Investment
Spermotile targets fertility clinics, integrates in workflow and improves IVF success from 24% to 36%. We are open to discuss investments.
Author
Krishna Agarwal
Professor (Physics), Founder (Spermotile)
Spermotile
Tromso, Norway
22 profile visitsEIC Beneficiary
I am a professor and a serial innovator in the microscopy domain. I am preparing to spin-off Spermotile, which is cultivating hope one star sperm at a time.
My organisation
As infertility rates rise globally, affecting 15% of couples, the demand for ART (Assisted Reproduction Technologies) has increased. But ART is demanding — physically, psychologically, and financially — with no guarantee of success. Selecting the highest quality sperm for fertilization can improve ART outcomes.
At Spermotile, we’re pioneering a breakthrough in Assisted Reproductive Therapy (ART). Our focus is on identifying the highest quality ‘star sperms’ from semen samples for use in ART. With a flourishing family of intellectual properties, we’re now developing the Spermotile filtration system that ensures the best outcomes for fertility treatments.
We will spin out and be market ready in 2027. We are looking for partners (investment, fertility clinics, production, distribution, sales, etc.).
About me
Agarwal is a professor in physics, specializing in computational microscopy. She is a serial innovator, spearheading 7 innovations in microscopy, biomaterials, and microscope consumables. She has received more than 13 Million Euros of public funding in Frontier Research (EU's ERC, Norwegian Research Council) and Innovation (EIC Pathfinder, Transition, etc.) portfolio. She is currently preparing to spin-out Spermotile, a revolutionary med-tech product to improve success of fertility treatments such as IVF.
Interests
- deep-tech, investment, sales strategy, networking